Keene L. Abbott

Oct 25, 2024 | biorxiv.org | Keene L. Abbott |Sonu Subudhi |Raphael Ferreira |Yetis Gultekin

AbstractCancer metastasis is a major contributor to patient morbidity and mortality, yet the factors that determine the organs where cancers can metastasize are incompletely understood. In this study, we quantify the absolute levels of over 100 nutrients available across multiple tissues in mice and investigate how this relates to the ability of breast cancer cells to grow in different organs.

Aug 18, 2024 | nature.com | Konstantine Tchourine |Keene L. Abbott |Florian Gourgue |Brian T. Do |Tenzin Kunchok |Allison Lau | +9 more

AbstractMetastases arise from subsets of cancer cells that disseminate from the primary tumour1,2. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and epigenetic changes that are important for disease initiation and progression, but these factors alone do not predict if and where cancers metastasize3,4. Specific cancer types metastasize to consistent subsets of tissues, suggesting that primary tumour-associated factors influence where cancers can grow.

Jun 3, 2024 | elifesciences.org | Robert Bradley |Helmut Bischof |Brandon Hayes |Keene L. Abbott

Request a detailed protocol We implemented an RSF model, an ensemble of multiple base learners (survival trees), using the randomForestSRC package (Ishwaran et al., 2008). The RSF algorithm is an extension of the Random Forest Algorithm (Breiman, 2001) for usage with right-censored data.

Dec 24, 2023 | biorxiv.org | Keene L. Abbott |Ahmed Ali |Bradley I. Reinfeld |Sonu Subudhi

AbstractThe tumor microenvironment is a determinant of cancer progression and therapeutic efficacy, with nutrient availability playing an important role. Although it is established that the local abundance of specific nutrients defines the metabolic parameters for tumor growth, the factors guiding nutrient availability in tumor compared to normal tissue and blood remain poorly understood.

Dec 4, 2023 | nature.com | Keene L. Abbott |Audrey J. Muscato |Kathleen B. Yates |Juan Dubrot |John G. Doench |Marcela V. Maus | +3 more

AbstractCAR-T therapy is a promising, novel treatment modality for B-cell malignancies and yet many patients relapse through a variety of means, including loss of CAR-T cells and antigen escape. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a modular guide RNA library.